Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-Label, Pharmacodynamic Study to Evaluate the Effect of Sotatercept (ACE-011) on Red Blood Cell Mass and Plasma Volume in Subjects With Solid Tumors

NCT01190644 is registered in ClinicalTrials.gov with Merck Sharp & Dohme LLC as lead sponsor.

NCT NCT01190644
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01190644 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-Label, Pharmacodynamic Study to Evaluate the Effect of Sotatercept (ACE-011) on Red Blood Cell Mass and Plasma Volume in Subjects With Solid Tumors
Lead sponsor
Merck Sharp & Dohme LLC
Phase
Phase 2
Overall status
Terminated
Start date
June 1, 2010
Completion date
October 29, 2012
Enrollment
5 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumors